We Ran A Stock Scan For Earnings Growth And Insulet (NASDAQ:PODD) Passed With Ease
Tandem Diabetes a New Equal Weight at Morgan Stanley Due to Competition
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $264
Insulet (PODD) Gets a Buy From TD Cowen
Eli Lilly's Mounjaro Cuts Risk of Developing Type 2 Diabetes, Study Finds
'Bottom-fishing' Ideas Within Piper Sandler's Universe of Stocks
Insulet to Present at Upcoming Investor Conferences
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
Insulin Pump Market Research Report 2024-2032 With Competitive Analysis of Medtronic, Insulet, Tandem Diabetes Care, Roche, Insulet, Ypsomed, and Microtech Medical
Insulet Corporation (PODD): This Diabetes Stock Is A Good Addition To Your Portfolio Now
Insulet (NASDAQ:PODD) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
The Latest Analyst Ratings For Insulet
Peering Into Insulet's Recent Short Interest
Express News | Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $220
A Look At The Fair Value Of Insulet Corporation (NASDAQ:PODD)
Barclays Sticks to Their Hold Rating for Insulet (PODD)
Insulet Second Quarter 2024 Earnings: Beats Expectations
Decoding Insulet Corp (PODD): A Strategic SWOT Insight